Sino Biopharmaceutical Dividends and Buybacks
Dividend criteria checks 3/6
Sino Biopharmaceutical is a dividend paying company with a current yield of 1.52% that is well covered by earnings. Next payment date is on 10th July, 2025 with an ex-dividend date of 16th June, 2025.
Key information
1.5%
Dividend yield
1.4%
Buyback Yield
| Total Shareholder Yield | 3.0% |
| Future Dividend Yield | 1.6% |
| Dividend Growth | 15.3% |
| Next dividend pay date | 10 Jul 25 |
| Ex dividend date | 16 Jun 25 |
| Dividend per share | n/a |
| Payout ratio | 62% |
Recent dividend and buyback updates
Sino Biopharmaceutical (HKG:1177) Is Increasing Its Dividend To CN¥0.04
May 23
Sino Biopharmaceutical (HKG:1177) Is Paying Out A Larger Dividend Than Last Year
Apr 30Sino Biopharmaceutical's (HKG:1177) Dividend Will Be Increased To CN¥0.04
Apr 06Sino Biopharmaceutical's (HKG:1177) Dividend Will Be Increased To CN¥0.04
Mar 23Recent updates
Sino Biopharmaceutical Limited (HKG:1177) Stocks Shoot Up 38% But Its P/E Still Looks Reasonable
Jun 13Sino Biopharmaceutical (HKG:1177) Is Increasing Its Dividend To CN¥0.04
May 23Sino Biopharmaceutical's (HKG:1177) Earnings Seem To Be Promising
May 06Sino Biopharmaceutical (HKG:1177) Is Paying Out A Larger Dividend Than Last Year
Apr 30Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?
Apr 27Sino Biopharmaceutical's (HKG:1177) Dividend Will Be Increased To CN¥0.04
Apr 06Sino Biopharmaceutical's (HKG:1177) Dividend Will Be Increased To CN¥0.04
Mar 23Getting In Cheap On Sino Biopharmaceutical Limited (HKG:1177) Might Be Difficult
Jan 13Is Sino Biopharmaceutical (HKG:1177) A Risky Investment?
Dec 08After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar
Oct 02Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly
Sep 02Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?
Jul 12Stability and Growth of Payments
Fetching dividends data
Stable Dividend: 1177's dividend payments have been volatile in the past 10 years.
Growing Dividend: 1177's dividend payments have increased over the past 10 years.
Dividend Yield vs Market
| Sino Biopharmaceutical Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (1177) | 1.5% |
| Market Bottom 25% (HK) | 2.8% |
| Market Top 25% (HK) | 7.3% |
| Industry Average (Pharmaceuticals) | 2.4% |
| Analyst forecast (1177) (up to 3 years) | 1.6% |
Notable Dividend: 1177's dividend (1.52%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.81%).
High Dividend: 1177's dividend (1.52%) is low compared to the top 25% of dividend payers in the Hong Kong market (7.34%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (62.2%), 1177's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (25%), 1177's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/30 10:30 |
| End of Day Share Price | 2025/06/30 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sino Biopharmaceutical Limited is covered by 53 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Liu | BNP Paribas Securities (Asia) |
| Ling Zhang | BNP Paribas Securities (Asia) |
| Bo Li | BofA Global Research |